Evidence map›Paper›PMID 39982634›Full record

ArticlePharmaceutical medicine2025

The Evolution of In-Field Medical Affairs: Introducing the Strategic Scientific Advisor.

Lucía Regadera Anechina, Inmaculada Iglesias, Jorge A Marinich, Jesús Diago, Ana Pérez Domínguez

Abstract read
In one paragraph

Article in Pharmaceutical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lucía Regadera AnechinaMedical Affairs Department, AstraZeneca Farmacéutica Spain, C. del Puerto de Somport 21-23, Fuencarral-El Pardo, 28050, Madrid, Spain.
Inmaculada IglesiasMedical Affairs Department, AstraZeneca Farmacéutica Spain, C. del Puerto de Somport 21-23, Fuencarral-El Pardo, 28050, Madrid, Spain.
Jorge A MarinichMedical Affairs Department, AstraZeneca Farmacéutica Spain, C. del Puerto de Somport 21-23, Fuencarral-El Pardo, 28050, Madrid, Spain.
Jesús DiagoMedical Affairs Department, AstraZeneca Farmacéutica Spain, C. del Puerto de Somport 21-23, Fuencarral-El Pardo, 28050, Madrid, Spain.
Ana Pérez DomínguezMedical Affairs Department, AstraZeneca Farmacéutica Spain, C. del Puerto de Somport 21-23, Fuencarral-El Pardo, 28050, Madrid, Spain. Ana.Perez.Dominguez@astrazeneca.com.ORCID 0009-0005-8636-5733

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The evolving landscape of healthcare demands a transformation in Medical Affairs (MA) to address new challenges and opportunities. This article presents the Strategic Scientific Advisor (SSA) role as a critical innovation within our MA department, aimed at enhancing early engagement with stakeholders and strategically positioning assets within the healthcare ecosystem. The SSA role was developed following a comprehensive external assessment and an internal review of the MA department's structure to integrate the CARABELA methodology, which serves as the foundation for SSA activities. CARABELA is a joint initiative between AstraZeneca and key scientific societies to optimize clinical practices in specific chronic diseases using a holistic strategy, whose implementation is monitored in each hospital by applying specifically designed indicators. The SSA role design, guided by the Strategic Scientific Area Plan Framework, emphasizes early proactive engagement, evidence generation, and a multidisciplinary approach to optimizing clinical practices. By fostering collaboration across internal teams and external partners, the SSA supports activities throughout the entire lifecycle of the product, facilitating early access strategies, and building tailored plans to address unmet medical needs. In contrast to traditional Medical Science Liaisons (MSLs), SSAs play pivotal roles in driving long-term healthcare outcomes, aligning with the Medical Affairs 2030 vision. The SSA is trained and evaluated to catalyze a strategic shift, enabling MA to address the complexities of healthcare ecosystems, improve clinical practices, and contribute to patient-centered innovations. This transformation underscores the critical need for MA professionals to expand beyond traditional responsibilities and lead initiatives that shape the future of healthcare.

Indexed as

Delivery of Health CareHumans

Identifiers

PMID39982634
PMCPMC11880172

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.